Published • loading... • Updated
Accent Therapeutics to Present Trial in Progress Poster for Phase 1/2 Study of ATX-295 at the 2026 American Society of Clinical Oncology Annual Meeting
Summary by The Billings Gazette
21 Articles
21 Articles
The Billings Gazette+20 Reposted by 20 other sources
Accent Therapeutics to Present Trial in Progress Poster for Phase 1/2 Study of ATX-295 at the 2026 American Society of Clinical Oncology Annual Meeting
Presentation highlights first clinical study of ATX-295, a potentially best-in-class oral KIF18A inhibitor, in patients with advanced or metastatic solid tumors
·Billings, United States
Read Full ArticleCoverage Details
Total News Sources21
Leaning Left1Leaning Right0Center13Last UpdatedBias Distribution93% Center
Bias Distribution
- 93% of the sources are Center
93% Center
C 93%
Factuality
To view factuality data please Upgrade to Premium
